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a b s t r a c t 
Conventional analytic methods used for tuberculosis (TB) outcomes research use standardized outcomes 
deﬁnitions and assess safety and eﬃcacy separately. These methods are subject to important limitations. 
Conventionally utilized outcome deﬁnitions fail to capture important aspects of patients’ treatment ex- 
perience and obscure meaningful differences between patients. Assessing safety and eﬃcacy separately 
fails to yield an objective risk–beneﬁt comparison to guide clinical practice. We propose to address 
these issues through an analytic approach based on prioritized outcomes. This approach enables a more 
comprehensive and integrated assessment of TB interventions. It simultaneously considers a “totality of 
outcomes”, including clinical beneﬁt, adverse events, and quality of life. These composite outcomes are 
ranked terms of overall desirability and compared using statistical methods for ordinal outcomes. Here 
we discuss the application of this approach to TB research, the considerations involved with prioritizing 
TB treatment outcomes, and the statistical methods involved in comparing prioritized outcomes. 
© 2016 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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2. Introduction 
Studies assessing different treatment strategies for tuberculosis
TB) typically use binary outcomes (e.g., successful versus unsuc-
essful treatment, death versus survival) based on a standardized
et of outcome deﬁnitions that were established to report TB pro-
ram data to the World Health Organization. Five mutually exclu-
ive outcomes are deﬁned: cured, treatment completed, treatment
ailed, died, and lost to follow-up [1] ( Table 1 ). 1 Treatment success
s typically deﬁned as either cured or treatment completed, which
ay poorly reﬂect how well a treatment works and how it con-
ributes to patient well-being. Moreover, these classiﬁcations are
ubject to several limitations when used for TB treatment research,
s they obscure meaningful differences between individual patientutcomes. 
∗ Corresponding author at: Francois Xavier Bagnoud (FXB) Building Room 517, 
51 Huntington Avenue, Boston, MA 02115-6017, USA. Tel.: + 1 617 432 1141; fax: 
 1 617 432 3163. 
E-mail address: gmontepie@sdac.harvard.edu (G. Montepiedra). 
1 These authors contributed equally to the work. 
1 This list excludes the categories of “Not evaluated,” which means that no treat- 
ent outcome has been assigned, and “Treatment success,” which is the sum of 
Cured” and “Treatment completed.”
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405-5794/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uFirstly, these deﬁnitions do not consider side effects during
reatment, so patients who complete treatment without any ma-
or side effects and patients who complete treatment but suffer ir-
eparable hearing loss are equivalently classiﬁed. Secondly, the def-
nitions do not consider the condition of a patient at the end of the
bservation period. Patients who complete treatment are classiﬁed
s treatment successes even if they are faring poorly clinically with
orsening radiographic ﬁndings at the end of treatment. Thirdly,
he deﬁnitions do not capture risk of relapse, which occurs after
he end of the prescribed treatment period but is arguably integral
o the deﬁnition of cure. Fourthly, for patients who are classiﬁed as
ailing treatment, the deﬁnitions do not capture the possibility for
etreatment. Because the ﬁrst event that occurs is used to deﬁne
he treatment outcome [2] , patients in the “treatment failed” cat-
gory may include those who ultimately died during the observa-
ion period and those who were ultimately cured [3] . And ﬁnally,
ecause the deﬁnitions only describe patients’ status at a single
ndpoint, they are ill-suited for incorporating indicators related to
he treatment experience, such as the length of treatment, the pill
urden, the dosing schedule, or the mode of administration (i.e.,
njectable versus oral). 
An alternative analytic approach that could address the chal-
enge of differentiating patient outcomes based on all meaningfulnder the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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Table 1 
World Health Organization reporting deﬁnitions for tuberculosis (TB) treatment outcomes. 
Outcome Deﬁnition for patients treated for TB susceptible to rifampin Deﬁnition for patients treated for TB resistant to at least rifampin 
(including multidrug-resistant TB) 
Cured A pulmonary TB patient with bacteriologically conﬁrmed TB at the 
beginning of treatment who was smear- or culture-negative in 
the last month of treatment and on at least one previous 
occasion 
Treatment completed as recommended by the national policy 
without evidence of failure AND three or more consecutive 
cultures taken at least 30 days apart are negative after the 
intensive phase of treatment 
Treatment completed A TB patient who completed treatment without evidence of failure 
BUT with no record to show that sputum smear or culture 
results in the last month of treatment and on at least on 
previous occasion were negative, either because tests were not 
done or because results are unavailable 
Treatment completed as recommended by the national policy 
without evidence of failure BUT no record that three or more 
consecutive culture taken at least 30 days apart are negative 
after the intensive phase of treatment 
Treatment failed A TB patient whose sputum smear or culture is positive at month 
5 or later during treatment 
Treatment terminated or need for permanent regimen change of at 
least two antituberculosis drugs because of one of four reasons 
(fully described in guidelines), which are related to lack of 
bacteriologic response, development of additional drug 
resistance, or adverse reactions to drug(s) 
Died A patient who dies for any reason before starting or during the 
course of treatment 
A patient who dies for any reason during the course of treatment 
Lost to follow-up A TB patient who did not start treatment or whose treatment was 
interrupted for 2 consecutive months or more 
A patient whose treatment was interrupted for 2 consecutive 
months or more 
Table adapted from World Health Organization, “Deﬁnitions and reporting framework for tuberculosis – 2013 revision” [1] . 
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Fig. 1. Hypothetical distribution of outcomes and serious adverse events among pa- 
tients treated with two regimens. 
p  
w  
l  
m  
e  
t  
B  
d  
t  
[  
t  
e
 
y  
p  
B
3
 
s  
r  
r  
p  
t  
f  
t  
T  
s
 
r  
c  comparisons is one based on prioritized outcomes. Prioritized
outcomes approaches consider each individual patient’s treatment
experience with respect to multiple types of clinical outcomes dur-
ing the entire period of observation (i.e., a “totality of outcomes”)
and then rank patients according to their overall treatment expe-
rience. Formal statistical comparisons are used to compare groups
of patients based on the ranks of their totality of outcomes. This
idea was ﬁrst proposed in the statistical literature by Chuang-Stein
in the context of clinical trials of antihypertensive drugs [4] .
Since then, a body of methodological work has been produced
in different disease areas [5–14] . More recently, Evans et al de-
scribed an adaptation of this approach in the context of antibiotic
stewardship trials [15] . In this concept paper, we describe how
prioritized outcome approaches can be used to assess a totality of
outcomes for TB treatment. 
2. Example 1: a prioritized outcomes approach to risk–beneﬁt 
analysis of TB treatments 
To illustrate the advantage of a prioritized outcome approach,
we present an example using a highly simpliﬁed scheme for rank-
ing outcomes of patients treated for multidrug-resistant (MDR) TB.
Many of the drugs available for treatment of MDR-TB are known
to have substantial toxicity, and MDR-TB treatment regimens are
poorly tolerated by patients. Clinicians are forced to subjectively
weight the risks and beneﬁts of using a regimen that may offer
a greater chance of cure but results in a higher risk of adverse
events. 
Let us consider two regimens, A and B, each used to treat
300 patients, and producing the simpliﬁed outcome distributions
shown in Fig. 1 . Regimen B is associated with a signiﬁcantly
higher treatment success rate compared to regimen A (73% versus
65%, relative risk [RR] for treatment success = 1.31, 95% conﬁdence
interval [CI] 1.03–1.67), but also a signiﬁcantly higher prevalence
of serious adverse events (50% versus 40%, RR for serious adverse
events = 1.20, 95% CI 1.04–1.39). Thus, a comparison based purely
on clinical beneﬁt would favor Regimen B, while a comparison
based purely on toxicity would favor Regimen A. The question
arises: Does the clinical beneﬁt derived from choosing Regimen B
outweigh the higher risk of serious adverse events associated with
it? 
A prioritized outcomes approach allows comparison of both
indicators simultaneously and, thereby, directly addresses this
risk–beneﬁt question. One must ﬁrst rank the desirability ofatient outcomes. In this case, let us consider: Treatment success
ithout adverse event > treatment success with adverse event >
ack of treatment success without adverse event > lack of treat-
ent success with adverse event. Categorizing the 300 patients in
ach group into these four categories, then comparing the ranks in
he two groups using the Wilcoxon rank sum tests, favors Regimen
 with a p-value of 0.018. The estimated probability that a ran-
omly selected patient taking Regimen B will have a better score
han a patient from Regimen A is 55.4% (95% conﬁdence interval
CI]: 52.8–57.9%) when all pairwise comparisons are included in
he estimation, with half a point added to the numerator of the
stimate whenever a tie occurs. 
Thus, while comparing clinical beneﬁt and toxicity separately
ields contradictory information about which regimen may be
referable, a prioritized outcome approach suggests that Regimen
 may be better overall, given these outcome distributions. 
. Prioritizing outcomes for TB research 
The example above presented a simplistic outcome ranking
cheme for illustrative purposes, but in actuality, the outcome
anking scheme could be much more complex. Developing this
anking scheme is the ﬁrst and most important step in applying a
rioritized outcome approach. It is important to acknowledge from
he outset that the act of ranking is inherently subjective and dif-
erent aspects of the treatment experience may be more important
o consider depending on the research question and study context.
herefore, it is critical to achieve consensus in creating this ranking
cheme before proceeding with analysis. 
A method that has been used to validate prioritized outcome
ankings for HIV [8] and cardiovascular disease [5] is to use
onsensus ranking to inform development of rule-based ranking
G. Montepiedra et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 9–13 11 
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Fig. 2. Hypothetical distribution of outcomes among 100 patients in each of two 
TB programs with equivalent treatment success rates. chemes. First, a panel of expert clinicians (or clinicians and
atients) is used to subjectively rank the outcomes of a set of
atients. These results are then used to inform development of
ultiple possible rule-based ranking schemes, which apply hierar-
hical sets of rules to differentiate patients ﬁrst based on primary
utcome indicators, then use secondary outcome indicators to
ifferentiate among patients with the same primary outcome
anking. The performance of each rule-based ranking scheme is
ompared against the experts’ rankings using Spearman’s rank cor-
elation, and the set of rules that produces a ranking most similar
o the clinicians’ judgement is identiﬁed. An alternative approach
ould be to use a Delphi process for achieving consensus among
xperts, or among experts and patients [16,17] . 
To illustrate some of the complexities involved in creating a
ule-based ranking scheme, we present one possible ranked list
f primary clinical outcomes, which seeks to integrate treatment
ompletion, bacteriologic response, and clinical response. In this
ist, 1 represents the most desirable outcome, and 6 the worst out-
ome. 
(1) Treatment completed with bacteriologic evidence of a sus-
tained cure. 
(2) Treatment completed without bacteriologic evidence of sus-
tained cure, but with radiologic improvement or resolution
of symptoms. 
(3) Treatment completed without bacteriologic evidence of sus-
tained cure, and with no radiologic improvement or resolu-
tion of symptoms 
(4) Treatment not completed, but patient did not die during
the set observation period, and suﬃcient bacteriological ev-
idence was available to determine that there was no relapse
within the observation period. 
(5) Treatment not completed, and patient did not die while re-
ceiving treatment, but either the patient relapsed within the
set observation period, or insuﬃcient bacteriologic evidence
was available to determine absence of relapse. 
(6) Death attributable to TB at any time during set observation
period. 
One major question that this list elicits is how to rank patients
n Outcome categories 3 and 4 relative to one another. While treat-
ent completion is generally seen as superior to lack of treat-
ent completion, one could argue that patients with Outcome 4
ared better than patients experiencing Outcome 3, who completed
 clinically ineffective treatment. If there is no clear distinction
n terms of superiority or inferiority between adjacent categories,
hen they could be combined. In addition, once secondary out-
omes such as side effects are taken into account, the situation
ight become more complex. As a secondary outcome measure,
ide effects would be expected to differentiate among patients ex-
eriencing the same primary outcome, but not to change the rel-
tive rankings of patients with different primary outcomes. How-
ver, differences of opinion could exist on whether a patient who
xperienced severe side effects but had bacteriologic evidence of
ure fared better than a patient who experienced no side effects
ut lacked bacteriologic evidence of cure. The inherent subjectivity
f the ranking process requires that any ranking scheme used for
nalysis ﬁrst be validated, and ideally, sensitivity analyses would
e conducted to determine the effect of re-ordering ranks among
ontested sets of outcomes. 
In addition to side effects, other aspects of the treatment ex-
erience that may be incorporated into a ranked list of totality of
utcomes include whether a patient is left with disease-associated
isability at the end of treatment, whether a patient acquired ad-
itional drug resistance during treatment, the total length of treat-
ent received, and the number of weeks the patient was unable
o work or attend school. However, one has to be careful incorpo-ating criteria that are of lesser importance into a ranking scheme,
s large differences in lesser criteria may obscure a meaningful dif-
erence in a more important criterion, or even possibly result in a
ifferent regimen being favored [18] . 
. Example 2: evaluation of TB program performance using 
rioritized outcomes 
The following example illustrates the added value of analyses
hat consider a totality of outcomes. Consider two TB programs
ith 75% treatment success rates ( Fig. 2 ). Program A lacks a robust
ystem for microbiologic follow-up and drug susceptibility testing
DST). As a result, a substantial proportion of patients complete in-
ffective regimens, and many treatment failures are either lost to
ollow-up or die. Program B has a system of microbiologic follow-
p and DST for those at risk of treatment failure, so many patients
n a failing regimen are ultimately switched to effective second-
ine regimens. 
Fig. 2 shows the hypothetical distribution of outcomes based
n the WHO classiﬁcation, as well as a new set of seven ranked
otality of outcomes, which are used to compare Programs A and
 using a prioritized outcomes approach. Using the WHO deﬁni-
ions, here is no signiﬁcant difference in treatment success rates
etween the two strategies (75% for both, relative risk [RR] for
reatment success = 1.00, 95% conﬁdence interval [CI] 0.85–1.17).
owever, comparison of the ranks between the two groups using
he Wilcoxon rank sum test favors Program B, with a p-value of
.038. The estimated probability that a patient in Program B will
12 G. Montepiedra et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 9–13 
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w  have a better rank than a patient in Program A is 58.4% (95% con-
ﬁdence interval [CI]: 55.5–61.6% when all pairwise comparisons are
included in the estimation. 
We see that reliance on the conventionally utilized outcome
deﬁnitions may not reveal differences in what ultimately happens
to patients, as illustrated in this hypothetical example that aims
to determine whether there is added value in a strategy of moni-
toring patients to assess the need for regimen changes during TB
treatment. Hence, a totality of outcomes approach that differenti-
ates among these different possibilities can show a difference in
program performance even in the absence of increased “treatment
success”. 
5. Overview of statistical methods 
Prioritized outcomes analyses use standard methods for analyz-
ing ordinal data, including Wilcoxon’s rank sum test or Cochran–
Mantel–Haenszel’s chi-square. As illustrated in the examples above,
the treatment effect can be quantiﬁed by estimating the probabil-
ity that a randomly selected patient in one arm will get a higher
score than a randomly selected patient in the other arm based
on comparison of all possible patient pairs. Conﬁdence intervals
around these estimates can be obtained using bootstrapping meth-
ods. Alternative measures of treatment effect based on pairwise
comparisons of patients between the two treatment arms have also
been proposed more recently, such as Buyse’s [10] “proportion in
favor” and Pocock et al.’s “win ratio” quantities [11] . 
Ordinal logistic regression can also be used to compare ranked
outcomes [19] . A constant odds ratio for all cumulative levels of
the ranked outcomes can be estimated, as long as the data sat-
isfy the proportional odds assumption. Otherwise, a model with
nonconstant odds ratios can be ﬁt, although this approach would
yield separate treatment effect estimates for the different cumula-
tive outcome categories. An advantage of the regression approach
is that one can readily adjust for the presence of potential con-
founders or signiﬁcant covariates, which is particularly important
when analyzing data from non-randomized studies or observa-
tional cohorts. Alternative approaches when the proportional odds
model ﬁts poorly are also discussed by Agresti [19] . 
For example, we use ordinal logistic regression to compare the
two regimens described in Example 1 above. We ﬁnd that the pro-
portional odds assumption does not hold for these data (score test
p -value < 0.0 0 01). However, the constant odds ratio estimate from
logistic regression modeling using cumulative logits is still useful
in providing an overall treatment effect measure [19] . In this case,
the odds ratio (OR) of 1.44 (95% CI: 1.07–1.92) shows that Regi-
men B is generally favored. Modeling with nonproportional odds
shows that Regimen B has signiﬁcantly higher odds of treatment
success without a serious adverse event than Regimen A (OR =
2.21, 95% CI: 1.58–3.10) and higher odds of treatment success with
or without a serious adverse event (OR = 1.48, 95% CI: 1.05–2.10);
however, Regimen B is associated with signiﬁcantly lower odds of
avoiding the worst outcome of treatment failure with a serious ad-
verse event (OR = 0.11, 95% CI: 0.06–0.23). 
One issue likely to be encountered in TB outcomes research,
given the lengthy duration of treatment, is how to compare out-
comes for patients who did not remain under observation for the
entire prescribed observation period. One method for dealing with
the complications of a censored outcome is to compare patient
pairs over the common follow-up period [9] . 
6. Discussion 
Conventionally utilized methods of assessing TB treatment out-
comes do not capture the multiple dimensions of the treatmentxperience that are meaningful in determining an optimal treat-
ent approach. Conventional analytic methods that use binary
reatment outcomes or rely on the standardized WHO outcome
ategories when comparing treatment strategies can fail to de-
ect meaningful differences between patient experiences and ﬁnal
utcomes. Determining optimal treatment strategies will require
ethods capable of simultaneously considering measurements of
ﬃcacy, safety, and patient quality of life. As a complementary ap-
roach to conventional methods, prioritizing and evaluating the to-
ality of outcomes over the long course of a patient’s treatment
nd follow-up could help provide a more comprehensive compari-
on of different treatment approaches. 
In the applications discussed, we presented two examples to
rovide a clear picture of the methodology and its application to
B treatment research. It will be necessary to develop robust repre-
entations of the totality of outcomes for TB treatment, which will
equire collaboration between methodologists and clinicians. While
ifferent research questions may require incorporation of different
utcomes measures into a prioritized outcome list, maintaining a
evel of standardization across similar studies is desirable to allow
omparisons across studies and to inform further research. In addi-
ion, work is needed to determine the robustness of these methods
hen applied to the outcome distributions observed for TB treat-
ent, including assessing the sensitivity of the results to changes
n the outcome prioritization scheme. 
If successfully applied, prioritized outcomes approaches for TB
esearch could prove informative to clinicians by enabling an ob-
ective method for weighing risk and beneﬁts against each other.
urrently, clinicians presented with separate comparisons of safety
nd toxicity are required to make subjective risk–beneﬁt assess-
ents, and one unintended result of this situation may be overly
onservative use of drugs (especially new drugs) because of a sub-
ective emphasis on safety risks over treatment beneﬁts. For ex-
mple, using regimens with more drugs may reduce the risk of
ortality and relapse [20,21] , but the additional side effects at-
ributed to the use of an additional drug may be deemed to out-
eigh any improvement of treatment outcomes. In addition, the
ew drugs bedaquiline and delaminid have recently been approved
or treatment of MDR-TB, but uptake has been conservative in part
ecause of concerns about the possibility of severe adverse events
ncluding death, even though these events were rare in clinical tri-
ls [22,23] . As illustrated in our example, assessing a totality of
utcomes could be particularly useful in informing these types of
ecisions. 
As in any methodological approach to comparing treatments,
his strategy is not without its challenges and limitations. One ma-
or consideration is how to create the ordered categories. There are
everal ways to elicit the prioritized outcomes, and some sugges-
ions are provided in Section 3 of this paper. There is also the pos-
ibility that a signiﬁcantly inferior treatment with respect to the
rimary clinical outcome will come out better due to improve-
ents in less important outcomes. A possibly effective way to ad-
ress this is to use a “partial credit” strategy that would exclude
 potentially inﬂuential but less important outcome in the prioriti-
ation scheme, and then directly assign its inﬂuence depending on
he resulting distribution of the ordinal outcome [24] . Another way
s to perform sensitivity analyses on the individual components, as
s done with other composite outcomes. On the whole, despite the
bove mentioned limitations, one should not be deterred from us-
ng an approach based on totality of outcomes since it can poten-
ially offer added value to the conventional analyses used in TB
esearch. 
As a research community, we should start by using this ap-
roach on available datasets in order to understand its behav-
or in the context of TB studies. The results of this preliminary
ork will not only help to develop these methods for TB outcomes
G. Montepiedra et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 9–13 13 
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ust make if we are to design future TB clinical trials using this
ew paradigm. 
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